Lastly, when investigating the synergistic effects of STAMBPL1 inhibition with αPD‐1 or sunitinib in renal cancer, it is preferable to utilize small molecule inhibitors targeting STAMBPL1 rather than employing STAMBPL1 KD tumor cells. This evidence concerns the gene STAMBPL1 and renal carcinoma.